Literature DB >> 9620546

Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.

I Bongarzone1, E Vigano, L Alberti, M G Borrello, B Pasini, A Greco, P Mondellini, D P Smith, B A Ponder, G Romeo, M A Pierotti.   

Abstract

Germline mutations of RET gene, encoding a receptor tyrosine kinase, have been associated with the MEN2A and MEN2B inherited cancer syndromes. In MEN2A mutations affecting cysteine residues in the extracellular domain of the receptor cause constitutive activation of the tyrosine kinase by the formation of disulfide-bonded homodimers. In MEN2B a single mutation in the tyrosine kinase domain (Met918Thr) has been identified. This mutation does not lead to dimer formation, but has been shown (both biologically and biochemically) to cause ligand-independent activation of the Ret protein, but to a lesser extent than MEN2A mutations. Intramolecular activation by cis-autophosphorylation of RetMEN2B monomers has been proposed as a model for activation, although alternative mechanisms can be envisaged. Here we show that the activity of RetMEN2B can be increased by stable dimerization of the receptor. Dimerization was achieved experimentally by constructing a double mutant receptor with a MEN2A mutation (Cys634Arg) in addition to the MEN2B mutation, and by chronic exposure of RetMEN2B-expressing cells to the Ret ligand GDNF. In both cases full activation of RetMEN2B, measured by 'in vitro' transfection assays and biochemical parameters, was seen. These results indicate that the MEN2B phenotype could be influenced by the tissue distribution or concentration of Ret ligand(s).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620546     DOI: 10.1038/sj.onc.1201759

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice.

Authors:  C Gestblom; D A Sweetser; B Doggett; R P Kapur
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Quantitative phenotyping as an efficient means to estimate C-cell number in a knock-in mouse model of MEN2B.

Authors:  Aaron Cranston; Louise Howard; C Vyvyan Howard
Journal:  Transgenic Res       Date:  2004-08       Impact factor: 2.788

Review 5.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

6.  The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Authors:  Carla Colombo; Emanuela Minna; Maria Grazia Rizzetti; Paola Romeo; Daniele Lecis; Luca Persani; Piera Mondellini; Marco A Pierotti; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  Orphanet J Rare Dis       Date:  2015-03-01       Impact factor: 4.123

7.  Tumor classification: molecular analysis meets Aristotle.

Authors:  Jules J Berman
Journal:  BMC Cancer       Date:  2004-03-17       Impact factor: 4.430

8.  HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Authors:  Setareh Safavi; Sofia Järnum; Christoffer Vannas; Sameer Udhane; Emma Jonasson; Tajana Tesan Tomic; Pernilla Grundevik; Henrik Fagman; Magnus Hansson; Zeynep Kalender; Alexandra Jauhiainen; Soheila Dolatabadi; Eva Wessel Stratford; Ola Myklebost; Mikael Eriksson; Göran Stenman; Regine Schneider-Stock; Anders Ståhlberg; Pierre Åman
Journal:  Oncotarget       Date:  2016-01-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.